Highlights Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-16 pm EDT			5-day change	1st Jan Change
14.16 ^USD	-5.22%		+2.39%	+57.51%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Highlights

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI
Mar. 02	Global markets live: Amazon, AWS, Lufthansa, Saudi Aramco, Standard Chartered…
Mar. 02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
Mar. 02	Intellia Therapeutics, Inc. Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM	CI
Feb. 26	Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Intellia Therapeutics Q4 Net Loss Narrows, Revenue Rises -- Shares Rise Pre-Bell	MT
Feb. 26	Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Net Loss $0.83 a Share, vs. FactSet Est of $0.95 Loss	MT
Feb. 26	Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q4 Revenue $23.0M, vs. FactSet Est of $12.0M	MT
Jan. 27	Intellia Therapeutics, Inc. Announces FDA Lift of Clinical Hold on Magnitude-2 Phase 3 Clinical Trial in Attrv-Pn	CI
Jan. 02	Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Nov. 10	Intellia Therapeutics, Inc. Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin Amyloidosis with Cardiomyopathy	CI
Nov. 08	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema	CI
Nov. 06	Intellia Q3 net loss narrows	RE
Nov. 06	Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q3 Revenue $13.8M, vs. FactSet Est of $14.1M	MT
Nov. 06	Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	US FDA places clinical hold on Intellia's gene therapy trials; shares fall	RE
25-10-29	Intellia, Inc. Provides Clinical Hold on the Investigational New Drug Applications for the Magnituda-2 Phase 3 Clinical Trials for Nexigur Ziclumeran	CI
25-10-27	The new silk road of optimism
25-10-27	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (Nex-z)	CI
25-10-27	Intellia pauses gene therapy trials after patient suffers liver injury, shares slide	RE
25-10-03	Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule	RE
25-09-25	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy	CI
25-09-22	Intellia Therapeutics, Inc. to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy	CI
25-09-18	Intellia Therapeutics, Inc. Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema	CI